Contractor profile
THE INSTITUTE FOR CANCER RESEARCH
Active registration
UEIFF1XVJMDYVR1
CAGE code1RAF4
Primary NAICS541720
LocationPHILADELPHIA, PA, 19111
Federal obligations$6M
Prime awards8
Active awards4
Latest award actionJul 21, 2026
Federal award activity
Public award recordTop federal customers
- Department of Health and Human Services8 awards$6M
NAICS award mix
- 5417147 awards$6M
- 5417151 awards$0
PSC award mix
- AN127 awards$6M
- 65051 awards$0
Contract vehicles
- 75N91019D000225 awards$6M
Potential recompetes
- Department of Health and Human Services$2M
- Department of Health and Human Services$1M
- Department of Health and Human Services$1M
- Department of Health and Human Services$1M
Prime award history
| Award | Agency / office | Category | Value | Dates |
|---|---|---|---|---|
| 75N91019D00022PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS (POP: 01/25/2019 -01/24/2024 | Department of Health and Human ServicesNIH NCI | NAICS 541714PSC AN12 | $0 | Jan 25, 2019 – Not stated |
| 75N91022F00002TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER | Department of Health and Human ServicesNIH NCI | NAICS 541714PSC AN12 | $1M | May 18, 2022 – Nov 17, 2026 |
| 75N92E21P00142THE ELNITSKI LAB IS PURCHASING NORMAL, LIVER, AND PROSTATE CANCER PATIENT PLASMA.[21-004028] | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHGRI | NAICS 541715PSC 6505 | $0 | May 3, 2021 – May 3, 2021 |
| 75N91024D00003PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ CONTRACT IN SUPPORT OF THE PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM | Department of Health and Human ServicesNIH NCI | NAICS 541714PSC AN12 | $0 | Jan 25, 2024 – Not stated |
| 75N91022F00001BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS TASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIATED COLORECTAL CANCER IMMUNOPREVENTION | Department of Health and Human ServicesNIH NCI | NAICS 541714PSC AN12 | $2M | Jun 15, 2022 – May 14, 2027 |
| 75N91023F00003PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS TASK ORDER TITLE: SULFORAPHANE FOR THE PREVENTION OF MALIGNANT MESOTHELIOMA | Department of Health and Human ServicesNIH NCI | NAICS 541714PSC AN12 | $1M | May 3, 2023 – May 2, 2027 |
| 75N91023F00001COLORECTAL CANCER (CRC) PREVENTION BY UROLITHIN A IN RODENT CRC MODELS | Department of Health and Human ServicesNIH NCI | NAICS 541714PSC AN12 | $1M | Jul 10, 2023 – Jul 9, 2027 |
| 75N91022F00003TASK ORDER TITLE: MICROBIAL METABOLITE MIMICRY, A NANO-DRUG FOR COLON CANCER PREVENTION PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS | Department of Health and Human ServicesNIH NCI | NAICS 541714PSC AN12 | $948,377 | Sep 15, 2022 – Jun 14, 2026 |
Award links and obligation totals come from USAspending.gov public records.
Industries and classifications
Public points of contact
KATHERINE LEVINSGovernment business
MARIA GILLDIRECTOR OF OFFICE OF SPONSORED RESEARCHAlternate government business
KATHRYN EVESElectronic business
Names and titles are reproduced from the public registration. FedRoster does not guess or enrich personal contact details.